Objectives: Pathologists are emerging as leaders in laboratory test utilization. We serve a critical role in guiding clinicians in selecting complex molecular hematology assays. We sought to understand and improve the practices at our institution through documenting our experience. Methods: The molecular assay for BCR-ABL1, which is detected in chronic myeloid leukemia (CML), and some cases of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), is frequently misordered. To help appropriately guide molecular tests in the care of BCR-ABL1+ acute leukemias, we retrospectively reviewed all BCR-ABL1+ acute leukemia cases assessed in our laboratory from January 2012 to January 2017. The 15 patients who presented with acute leukemia (14 B-ALL, one AML) all had BCR-ABL1 minor (p190). Results: We observed inappropriate orders for 11 patients. Hematologists ordered BCR-ABL1 major (p210) quantification on seven BCR-ABL1 minor patients who did not have BCR-ABL1 major. Duplicative BCR-ABL1 qualitative tests included three patients whose qualitative test was ordered twice at initial presentation. In two instances, our in-house leukemia panel (Hemavision), which includes BCR-ABL1 was also ordered. Our laboratory notified the hematologists and cancelled the redundant orders. In a situation where the qualitative test, was separately ordered through a reference laboratory, and in a different situation where a patient had both bone marrow aspirate and peripheral blood orders, our laboratory was unable to intervene. Conclusion: Inappropriate orders, such as what we observed (11 of 15; 73%), waste valuable medical resources without improving patient care. Our laboratory has since collaborated with hematology to develop an ordering algorithm to help promote appropriate molecular testing. As molecular assays become standard of care, pathologists can help clinicians appropriately incorporate molecular tests into clinical practice. Testing algorithms, such as those our laboratory has developed, will enhance healthcare value by reducing unnecessary testing, promoting cost savings, and accelerating the diagnostic process. , portend increased risk of breast cancer. Excision is typically standard; however, as these lesions are risk markers, not cancer, patients may have to wait for next steps in care, leading to patient anxiety and feelings of neglect. We aimed to provide patients with comprehensible information on their diagnoses in attempt to ease anxiety. Methods: Patients with first diagnoses of breast atypia (7/2015-1/2017) were each mailed a copy of her pathology report along with a one-page information sheet on her diagnosis. Patients were given a survey at the first clinic visit to assess the following: receipt of mailing, value of information, and patient comprehension. Results: The 40 patients with first diagnoses of atypia included 21 (52.5%) ADHs, eight (20%) LNs, six (15%) FEAs, one (2.5%) AA, two (5%) ADH and LN, one (2.5%) LN and FEA, and one (2.5%) ADH and FEA. Of the 40, 38 (95%) patients received surveys at first visit (one declined an appointment, and one was seen 6 days after diagnosis, prior to clinic notification of need for survey). Mean time from diagnosis to appointment was 29 days (range 6-121). Thirty-eight (95%) patients underwent excision with mean time to surgery of 66 days (range 21-140). Eighteen of 38 (47.4%) patients returned surveys. Of the 17 (94.4%) reported to have received the mailing, 16 (88.9%) reported that it was helpful and understandable, and 14 (77.8%) reported that they "did not have breast cancer" (note: one patient only answered the question asking whether she received the report). Conclusions: Patient-friendly pathology reports are beneficial for patients with breast atypias; this is likely also true for patients with other diagnoses, especially those who typically have delays from diagnosis to next steps in care.
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Clinicopathologic Study of Isolated Colitis in Periappendiceal Orifice Region: Further Evidence of Association With Nonsteroidal Anti-inflammatory Drugs
Alia Gupta, Wei Li, MD; William Beaumont Hospital, Royal Oak, MI Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been known to cause various gastrointestinal symptoms and histopathological changes. Limited evidence shows association of NSAID usage with isolated colitis in periappendiceal orifice region. This study evaluated the clinicopathologic features of 17 patients with isolated colitis limited to the periappendiceal orifice region. Materials and Methods: A retrospective review was performed on biopsy specimens from 17 patients (ranging from 19 to 76 years of age, with male to female ratio of 1.5:1.0) with histologically proven colitis (focal active colitis with no significant chronicity) limited to the cecum or periappendiceal orifice. No pathological abnormalities were identified in adjacent terminal ileum or other parts of colon in all these cases. Patients with history of colorectal tumor or inflammatory bowel diseases were excluded from the study. Relevant clinical history, endoscopic findings, and follow-up study were evaluated. Results: The main endoscopic findings included erythema, focal inflammation, erosion, and ulcerations in the cases studied. Among 17 cases, seven cases (41%) had documented histories of regular NSAID intake. Five of these seven patients demonstrated resolution of pathological abnormality after cessation of the drugs on repeated colonoscopy. Nine patients (53%) gave a history of occasional NSAIDs usage. One patient of these nine developed persistent lower gastrointestinal tract symptoms. None of the studied patients were found to have any infectious disease of gastrointestinal tract or inflammatory bowel disease, even on follow-up examination. Conclusion: Our results confirm the previously reported findings of a close association of isolated colitis in periappendiceal orifice region with NSAIDs. Our data further suggest that pathological changes of the isolated colitis are reversible after the cessation of the NSAIDs.
